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ABSTRACT
Objective Tumour necrosis factor alpha (TNF-α) plays 
an important role in rheumatoid arthritis (RA). TNF-α is 
synthesised as a membrane-anchored precursor and is 
fully activated by a disintegrin and metalloproteinase 17 
(ADAM17)-mediated ectodomain shedding. Nardilysin 
(NRDC) facilitates ectodomain shedding via activation of 
ADAM17. This study was undertaken to elucidate the role 
of NRDC in RA.
Methods NRDC-deficient (Nrdc–/–) mice and macrophage-
specific NRDC-deficient (NrdcdelM) mice were examined 
in murine RA models, collagen antibody-induced arthritis 
(CAIA) and K/BxN serum transfer arthritis (K/BxN STA). 
We evaluated the effect of gene deletion or silencing of 
Nrdc on ectodomain shedding of TNF-α in macrophages 
or monocytes. NRDC concentration in synovial fluid from 
patients with RA and osteoarthritis (OA) were measured. 
We also examined whether local gene silencing of Nrdc 
ameliorated CAIA.
Results CAIA and K/BxN STA were significantly attenuated 
in Nrdc–/– mice and NrdcdelM mice. Gene deletion or 
silencing of Nrdc in macrophages or THP-1 cells resulted 
in the reduction of TNF-α shedding. The level of NRDC is 
higher in synovial fluid from RA patients compared with 
that from OA patients. Intra-articular injection of anti-
Nrdcsmall interfering RNA ameliorated CAIA.
Conclusion These data indicate that NRDC plays crucial 
roles in the pathogenesis of autoimmune arthritis and 
could be a new therapeutic target for RA treatment.
IntroductIon
Rheumatoid arthritis (RA) is a chronic 
inflammatory disease that causes joint inflam-
mation and destruction affecting 0.5%–1.0% 
of the population.1 Anti-tumour necrosis 
factor alpha (TNF-α) biologic agents have 
led to a revolutionary improvement in the 
management of RA patients, indicating that 
this inflammatory cytokine plays a key role in 
RA pathogenesis. The importance of TNF-α 
has been also demonstrated in murine models 
of RA; for example, human TNF-α transgenic 
mice develop arthritis,2 TNF-α is produced 
in synovial tissues of murine experimental 
models of RA,3 murine experimental arthritis 
is attenuated in TNF-α-deficient mice4 
and neutralisation of TNF-α ameliorates 
murine collagen-induced arthritis.5 TNF-α 
is produced mostly by macrophages in RA 
synovial tissues6 and, alone or in combination 
with other cytokines or chemokines, recruits 
inflammatory cells such as B cells, T cells and 
neutrophils, and induces production of cyto-
kines, chemokines, matrix metalloproteinases 
or receptor activator of nuclear factor κB 
ligand, resulting in joint inflammation and 
bone resorption.7–11
One of the earliest subclinical features of RA 
is a breakdown of self-tolerance. Autoantibodies 
such as rheumatoid factor (RF) and anti-citrul-
linated peptide antibody (ACPA) are found in 
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Animal models
Key messages
What is already known about this subject?
 ► Tumour necrosis factor alpha (TNF-α), which 
is activated by ectodomain shedding, plays an 
important role in rheumatoid arthritis (RA).
 ► Nardilysin facilitates TNF-α shedding via enhancing 
a disintegrin and metalloproteinase 17 activity.
What does this study add?
 ► Deletion or inhibition of nardilysin prevents 
autoantibody-induced arthritis, murine models of 
RA.
 ► Concentration of nardilysin in synovial fluid is 
markedly increased in patients with RA compared 
with that in patients with osteoarthritis, suggesting 
a crucial role of nardilysin in the pathogenesis of RA.
How might this impact on clinical practice?
 ► Nardilysin could be a novel biomarker and 
therapeutic target for RA.
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the patients’ serum long before arthritis occurs.12 While the 
autoantigens have not been fully identified, autoantibodies 
may contribute to the pathogenesis of RA via immunocom-
plex (IC) formation and deposition in synovial tissues.13 
The importance of autoantibodies has been demonstrated 
in mouse autoantibody-induced arthritis (AAIA) models of 
RA, such as collagen antibody-induced arthritis (CAIA) and 
K/BxN serum transfer arthritis (K/BxN STA). Antibodies 
against intra-articular antigens, type II collagen in CAIA14 15 
and glucose-6-phophoisomerase in K/BxN STA16 17 are arthro-
genic in mice. TNF-α has been demonstrated to be important 
in both models: anti-TNF-α antibody attenuates CAIA,18 while 
TNF-α-deficient mice are resistant to K/BxN STA.4
Importantly, TNF-α is synthesised as a membrane-an-
chored precursor and is fully activated by a disintegrin and 
metalloproteinase 17 (ADAM17)-mediated ectodomain 
shedding,19 indicating that ADAM17 is an attractive alter-
native target for treatment of RA. However, the multiple 
disease phenotypes of ADAM17-deficient patients and mice 
have raised concerns about the potential adverse effects of 
anti-ADAM17 therapy.20 21 We have previously shown that 
ADAM17 activity and TNF-α shedding are enhanced by 
nardilysin, N-arginine dibasic convertase (NRDC), via its 
direct binding to ADAM17.22–24
NRDC is a zinc peptidase of the M16 family that selec-
tively cleaves dibasic sites.25 26 We identified NRDC on 
the cell surface as a specific binding partner of hepa-
rin-binding epidermal growth factor (EGF)-like growth 
factor (HB-EGF) and demonstrated that NRDC enhances 
ectodomain shedding of HB-EGF.27 Our subsequent 
studies revealed that NRDC enhances ectodomain shed-
ding of not only HB-EGF but also a wide range of other 
membrane proteins including TNF-α,23 28 neuregulin 129 
and amyloid precursor protein.22 We have also demon-
strated that NRDC-induced ectodomain shedding plays 
critical roles in myelination, gastric cancer and Alzhei-
mer’s disease.22–24 28–31
We demonstrate here that NRDC-deficient (Nrdc–/–) 
mice and macrophage-specific NRDC-deficient (NrdcdelM) 
mice show attenuation of AAIA. We also demonstrate 
that gene deletion or silencing of Nrdc in mouse macro-
phages or human monocytic cells results in reduction 
of TNF-α shedding. Importantly, the level of NRDC is 
increased in synovial fluid from RA patients compared 
with that from osteoarthritis (OA) patients. Moreover, 
intra-articular injection of anti-Nrdc small interfering 
RNA (siRNA) ameliorates CAIA. Together, these data 
suggest that NRDC controls AAIA via the regulation of 
TNF-α shedding and could be a new therapeutic target 
for RA treatment.
MaterIals and Methods
The full methods are provided in the online supplemen-
tary material. 
Blood and synovial fluid collection
Synovial fluid was obtained during joint surgery from 
20 patients with RA and 17 patients with OA, who had 
been admitted to Kyoto University Hospital. All of the RA 
patients met 2010 American College of Rheumatology 
and European League against Rheumatism (ACR/
EULAR) classification criteria for RA. Peripheral blood 
samples were obtained and the level of C-reactive protein 
(CRP), erythrocyte sedimentation rate (ESR), RF, and 
ACPA was examined before surgery. Disease activity score 
28 (DAS28) was calculated according to the results of 
physical examinations and blood tests.32 The full methods 
are provided in the online supplementary material.
results
Nrdc-deficient mice are resistant to CAIA
To explore the role of NRDC in RA, we compared wild-
type (WT) and Nrdc–/– mice with a BALB/c background 
using the CAIA model. After the intraperitoneal admin-
istration of a five-clone cocktail of monoclonal anti-type 
II collagen antibodies, we assessed the severity of arthritis 
daily for 2 weeks. The onset of arthritis was delayed (on 
day 3 in WT mice and on day 6 in Nrdc–/– mice, respec-
tively) and the average of arthritis score was significantly 
and markedly lower in Nrdc–/– mice (figure 1A,B). Ankle 
thickness was also significantly less in Nrdc–/– mice from 
days 4 to 9 compared with that in WT mice. Histological 
examination of the ankle joints demonstrated that syno-
vial hypertrophy with infiltration of inflammatory cells 
and bone and cartilage erosion were reduced or absent 
in Nrdc–/– mice (figure 1C). These results suggest that 
NRDC is crucial for AAIA development and progression.
Macrophage-specific Nrdc-deficient mice are resistant to 
caIa
Because macrophages play an important role in the 
pathogenesis of RA, we next generated NrdcdelM mice by 
crossing Nrdcflox/flox mice with Lyz2-Cre mice, in which Cre 
recombinase is expressed under the control of the lyso-
zyme 2 gene (Lyz2) promoter. Because the Nrdcflox/flox and 
NrdcdelM mice have a C57BL/6 genetic background, which 
is more resistant to CAIA than BALB/c, we administered 
2.5 times more antibody to Nrdcflox/flox and NrdcdelM mice 
for the CAIA experiments compared with the amount 
that was used for the Nrdc–/– mice. The results showed 
that the onset of arthritis was delayed and the severity 
of arthritis was markedly reduced in NrdcdelM mice 
compared with controls (figure 2A, B). As was the case 
for Nrdc–/– mice, synovial hypertrophy and bone erosion 
were attenuated in NrdcdelM mice (figure 2C). These find-
ings demonstrated that macrophage-specific deletion of 
NRDC almost completely recapitulated the resistance of 
Nrdc–/– mice to CAIA.
arthritis in the K/Bxn sta model is attenuated in NrdcdelM 
mice
To confirm the role of NRDC in autoimmune arthritis, 
we examined Nrdcflox/flox and NrdcdelM mice in another 
murine model, the K/BxN STA model. K/BxN mouse 
serum has been reported to strongly induce arthritis in a 
wide range of mouse strains.33 As shown in figure 2D,E, 
group.bmj.com on July 13, 2017 - Published by http://rmdopen.bmj.com/Downloaded from 
3Fujii T, et al. RMD Open 2017;3:e000436. doi:10.1136/rmdopen-2017-000436
Animal models
Figure 1 CAIA is attenuated in Nrdc–/– mice. (A) Photographs of the hind paws 4 days and 7 days after the induction of CAIA. 
Upper panels, wild-type (WT); lower panels, Nrdc–/– mice. (B) Arthritis score (upper) and ankle thickness (lower) were measured 
daily after the induction of CAIA. n=5 per genotype (mean ± SEM). *p<0.05; **p<0.01, Welch’s t-test. (C) H&E staining of the 
ankle joints 14 days after the induction of CAIA in WT (upper panels) and Nrdc–/– (lower panels) mice. Scale bars: 500 µm in 
the 40× magnification and 200 µm in the 100× magnification. Symbols in the 100x magnification images: arrow, bone erosion; 
arrow head, cartilage erosion; *, hypertrophic synovium.
K/BxN STA was significantly attenuated in NrdcdelM mice 
up to day 8 after injection. In contrast, there were no 
significant differences between Nrdcflox/flox and NrdcdelM 
mice in the arthritis score after day 9 or in ankle thick-
ness, although both values tended to be lower in NrdcdelM 
mice (figure 2D,E). The histology of the hind paws at 
day 14 demonstrated that the synovial hypertrophy with 
infiltration of inflammatory cells, bone erosion and 
cartilage erosion were equivalently observed in both 
Nrdcflox/flox mice and NrdcdelM mice (figure 2F), which is 
consistent with the results of arthritis score and ankle 
thickness. Collectively, these data demonstrated that 
NRDC deficiency in macrophages attenuated the 
severity of arthritis in two different experimental models 
of AAIA.
secretion of tnF-α from macrophages and monocytic cells 
is reduced by the deletion of Nrdc
Because macrophages are a major source of TNF-α in 
AAIA34 and NRDC facilitates ectodomain shedding of 
TNF-α,23 we hypothesised that the attenuation of AAIA 
in Nrdc–/– mice and NrdcdelM mice was due to the impair-
ment of ectodomain shedding of TNF-α in macrophages. 
To test this hypothesis, we first examined TNF-α secre-
tion from NRDC-deficient macrophages. We harvested 
bone marrow derived macrophages (BMDMs) from 
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Figure 2 Macrophage-specific Nrdc-deficient (NrdcdelM) mice are resistant to CAIA and K/BxN STA. (A) Photographs of the 
hind paws 4 days and 7 days after the induction of CAIA. Upper panels, Nrdcflox/flox; lower panels, NrdcdelM mice. (B) Arthritis 
score (upper) and ankle thickness (lower) were measured daily after the induction of CAIA. n=5 per genotype (mean ± SEM). 
*p<0.05; **p<0.01, Welch’s t-test. (C) H&E staining of the ankle joints 14 days after the induction of CAIA in Nrdcflox/flox (upper 
panels) and NrdcdelM (lower panels) mice. Scale bars: 500 µm in the 40× magnification and 200 µm in the 100× magnification. 
Symbols in the 100x magnification images: arrow, bone erosion; *, synovial hypertrophy. (D) Photographs of the hind paws 3 
days and 5 days after the induction of K/BxN STA. Upper panels, Nrdcflox/flox; lower panels, NrdcdelM mice. (E) Arthritis score 
(upper) and ankle thickness (lower) were measured daily after the induction of K/BxN STA. n=4 per genotype (mean ± SEM). 
*p<0.05; **p<0.01, Welch’s t-test. (F) H&E staining of the ankle joints 14 days after the induction of K/BxN STA in Nrdcflox/
flox (upper panels) and NrdcdelM (lower panels) mice. Scale bars: 500 µm in the 40× magnification and 200 µm in the 100× 
magnification. Symbols in the 100× magnification images: arrow, bone erosion; arrow head, cartilage erosion; *, synovial 
hypertrophy.
Nrdcflox/flox and NrdcdelM mice and confirmed that NRDC 
protein expression was remarkably reduced in BMDMs 
from NrdcdelM mice (figure 3A). BMDMs were stimu-
lated with or without a low concentration (10 ng/mL) 
of lipopolysaccharide (LPS), then the concentration 
of secreted TNF-α in the supernatants and the levels of 
TNF-α messenger RNA (mRNA) in BMDMs were exam-
ined. The results showed that there was no significant 
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Figure 3 Secretion of TNF-α from macrophages and monocytic cells were reduced by the deletion of Nrdc. (A) Western blot 
analysis of NRDC in BMDM from Nrdcflox/flox (left) and NrdcdelM mice (right). β-Actin was used as a loading control. (B) TNF-α 
mRNA levels in unstimulated or LPS-stimulated BMDMs were analysed by reverse transcription and quantitative PCR (qRT-
PCR). β-Actin mRNA levels were used as internal control. n=6 (mean ± SEM). (C) TNF-α secreted from BMDMs in conditioned 
medium was measured by ELISA. n=6 (mean ± SEM). (D) Membrane-bound TNF-α in BMDMs was stained 3 hours after LPS 
stimulation and analysed by flow cytometry. Filled histogram, unstimulated control; blue open histogram, Nrdcflox/flox; red 
open histogram, NrdcdelM. Representative histograms out of four independent experiments are shown. (E) ADAM17 mRNA 
levels in unstimulated or LPS-stimulated BMDMs were analysed by qRT-PCR. β-Actin mRNA levels were used as internal 
control. n=6 (mean ± SEM). (F) NRDC mRNA levels in THP-1 cells, transfected with lentiviral vectors for negative control 
RNA interference (RNAi) (control microRNA (miR)) or RNAi targeting Nrdc (anti-NRDC miR), were analysed using qRT-PCR. 
β-Actin mRNA was used as an internal control. n=6 (mean±SEM). (G) NRDC and ADAM17 protein expressions in THP-1 cells 
transfected with lentiviral vectors for control miR (left) or anti-NRDC miR 1 (right) were analysed by Western blot. β-Actin 
was used as a loading control. (H) TNF-α mRNA levels in THP-1 cells, transfected with lentiviral vectors as described in (G), 
were analysed using qRT-PCR. n=8 (mean ± SEM). (I) Secreted TNF-α (conditioned medium) and cell-contained TNF-α (cell 
extracts) in THP-1 cells described above were measured by ELISA. n=8 (mean±SEM). (J) F4/80 expression in peritoneal 
macrophage (PMs). Filled histogram, isotype control; open histogram, F4/80. Representative histograms out of three 
independent experiments are shown. (K) NRDC expression in PMs, isolated from Nrdcflox/flox (left) and NrdcdelM mice (right) after 
the reverse passive Arthus reaction, was examined by Western blot. β-Actin was used as a loading control. (L) Membrane-
bound TNF-α was stained and analysed by flow cytometry. Filled histogram, unstimulated control; blue open histogram, 
Nrdcflox/flox; red open histogram, NrdcdelM. Representative histograms out of three independent experiments are shown. (M) 
Measurement of secreted TNF-α concentration in the peritoneal lavage of Nrdcflox/flox (n=5), NrdcdelM (n=5) and control (n=4) 
mice. *p<0.05; **p<0.01, Welch’s t-test. 
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Table 1 Patients’ characteristics
OA RA
(n=17) (n=20) p Value
Age (years) 78±4.94 65.8±10.6 <0.01‡
Female (%) 14 (82.4) 16 (80) 0.999§
CRP (mg/dL) 0.0.69±0.079¶ 1.845±1.88 <0.01‡
ESR (mm/hour) 24.4±14.6# 47.3±35.0 0.014‡
DAS28-ESR 4.25±1.12
RF (U/mL) 73.5 (18.6 to 
189.1)
ACPA positive (%) 19 (95)
OA grading*
Grade I or II (%) 1 (5.9)
Grade III or IV (%) 16 (94.1)
RA stage†
Stage I or II (%) 7 (35)
Stage III or IV (%) 13 (65)
Data are presented as mean±SD, n (%) or median (IQR).
*The Kellgren-Lawrence Grading Scale.
†The Steinbrocker Staging system.
‡Data was not available in one patient.
§Data was not available in two patients.
¶Fisher’s exact test.
#Welch’s t-test.
Notably, the level of TNF-α in RA synovial fluid had a tendency of 
positive correlation with the level of NRDC (p=0.054), suggesting 
the causative role of NRDC in TNF-α elevation (figure 4C). We 
next analysed the association of NRDC levels in RA synovial fluid 
with the patients’ clinical condition. Interestingly, NRDC levels 
showed a significant but modest correlation with CRP levels, but 
no correlations with other factors including ESR, disease activity 
(disease activity score 28 (DAS28)-ESR), RF or ACPA (figure 4D 
and data not shown). These data suggested that NRDC could be 
a unique synovial fluid marker for the differential diagnosis of late 
RA and late OA.
difference in the mRNA level, but that there was a 
significant decrease in TNF-α secretion from NRDC-de-
ficient BMDMs at 3 hours after stimulation (figure 3B,C). 
Because impairment of TNF-α shedding leads to accu-
mulation of membrane-bound TNF-α,35 we analysed 
the cell surface expression of TNF-α on BMDMs by flow 
cytometry and found that membrane-bound TNF-α was 
increased in BMDMs from NrdcdelM mice (figure 3D). 
ADAM17 is essential for TNF-α shedding, and we previ-
ously reported that NRDC enhances the sheddase activity 
of ADAM17 via a direct interaction. Consistent with this, 
there were no significant differences in ADAM17 mRNA 
levels between BMDMs from Nrdcflox/flox and NrdcdelM mice 
(figure 3E).
We next assessed the effect of NRDC gene knockdown 
in a human monocytic cell line, THP-1. Efficient inhibi-
tion of NRDC mRNA and protein levels was confirmed 
in THP-1 cells infected with lentiviral vectors expressing 
RNAi targeting NRDC (figure 3F,G). LPS-induced TNF-α 
secretion in the supernatants was significantly decreased 
by gene knockdown of NRDC, whereas TNF-α mRNA 
levels and TNF-α protein concentrations in the cell 
lysates did not differ between control and NRDC-knocked 
down cells (figure 3H,I). Together, our results in mouse 
macrophages and human monocytic cells suggested that 
TNF-α activation via ectodomain shedding was inhibited 
by the deletion of NRDC.
To assess the in vivo role of NRDC on TNF-α secre-
tion in a way more relevant to disease, we examined the 
effect of immunocomplexes (ICs) on TNF-α secretion. 
In the mechanism of AAIA, inflammatory cells are acti-
vated by ICs that are deposited in the joints. To mimic 
this response, we applied a reverse passive Arthus reac-
tion peritonitis36 model to Nrdcflox/flox and NrdcdelM mice. 
In this model, ovalbumin (OVA) and anti-OVA antibody 
are administered separately, and then combine to make 
ICs and trigger complement pathways. We confirmed 
that cells collected from peritoneal lavage 3 hours after 
the administration were mostly F4/80 positive, and there-
fore were peritoneal macrophages (PMs) (figure 3J). 
We also confirmed that NRDC expression was markedly 
reduced in PMs from NrdcdelM mice (figure 3K), and 
analysis by flow cytometry demonstrated that membrane-
bound TNF-α was increased in PMs from NrdcdelM mice 
(figure 3L). In contrast, secreted TNF-α in the peritoneal 
lavage was lower in NrdcdelM mice than in Nrdcflox/flox mice 
(figure 3M). These results indicated that ectodomain 
shedding of TNF-α was impaired in NRDC-deficient 
macrophages.
nrdc increased in synovial fluid of patients with ra
To assess the pathophysiological role of NRDC in patients, 
we collected synovial fluid from patients with RA or OA 
during joint surgery. Intriguingly, we found a remarkable 
and significant elevation of the level of NRDC and TNF-α 
in synovial fluid from RA patients compared with that 
from OA patients (table 1, figure 4A,B).
Gene silencing of Nrdc in the ankle joints ameliorated caIa 
in Wt mice
To confirm the pathological role in vivo of NRDC in 
autoimmune arthritis, we examined whether local gene 
silencing of Nrdc ameliorated CAIA. We first tested 
three siRNAs targeting Nrdc in three different cell lines 
(RAW264.7, WEHI 13 VAR and mouse embryonic fibro-
blasts) and selected the siRNA with the best silencing 
efficacy (siRNA3) (figure 5A). This anti-Nrdc siRNA was 
injected into the left ankle joint of mice 2 days after 
CAIA induction, while negative control siRNA was 
injected into the right ankle joint. The results showed 
that the severity of arthritis was clearly reduced in the 
left joint (anti-NRDC siRNA) compared with the right 
joint (control siRNA) (figure 5C). The measurement 
of ankle thickness revealed that anti-Nrdc siRNA signifi-
cantly ameliorated CAIA from days 3 to 8 and days 12 
to 14 (figure 5D).
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Figure 4 NRDC and TNF-α increase in synovial fluid from patients with RA. (A) NRDC concentration in synovial fluid from 
OA (n=17) and RA (n=20) patients. **p<0.01, Welch’s t-test. (B) TNF-α concentration in synovial fluid from OA and RA patients. 
**p<0.01, Welch’s t-test. (C) NRDC in synovial fluid has a tendency of positive correlation with TNF-α in RA patients. Solid 
line, approximate line; broken line, 95% CI. r=0.44, p=0.054, Spearman’s rank correlation test. (D) NRDC in synovial fluid is 
significantly correlated with CRP in RA patients. Solid line, approximate line; broken line, 95% CI. r=0.50, p<0.05, Spearman’s 
rank correlation test. 
Figure 5 Intra-articular Nrdc gene silencing with siRNA attenuates CAIA. (A) Screening of siRNAs against NRDC in RAW264.7, 
WEHI 13 VAR and mouse embryonic fibroblasts (MEF). (B) Schedule of the induction of CAIA and intra-articular injection of 
siRNA. (C) Photographs of the hind paws 4 days after the induction of CAIA. Anti-NRDC siRNA was injected in the left ankle, 
while control siRNA was injected in the right ankle joints of BALB/c WT mice. (D) Ankle thickness was measured daily after the 
induction of CAIA (n=5 per treatment). *p<0.05, Welch’s t-test. 
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dIscussIon
In this study, we demonstrate for the first time in vivo 
that NRDC plays important roles in autoimmune 
arthritis. First, Nrdc–/– mice were resistant to CAIA, and 
resistance to two models of AAIA, CAIA and K/BxN 
STA, was confirmed in NrdcdelM mice, indicating that 
NRDC in macrophages is crucial for the pathogenesis 
of autoimmune arthritis. In both CAIA and K/BxN STA 
models, inhibition of TNF-α has been shown to attenuate 
arthritis.4 18 Given that macrophages are a major source 
of TNF-α in the joints, reduced release of TNF-α from 
NRDC-deficient macrophages may strongly contribute to 
the attenuation of arthritis.6
TNF-α is synthesised as a type 2 membrane protein 
precursor, which is cleaved by ADAM17 at a juxtamem-
brane domain to be released from the cell surface. A 
comparison of the phenotypes of TNF-α-null mice and 
knockin mice expressing an uncleavable form of TNF-α 
(mice without soluble TNF-α) revealed that soluble TNF-α 
is dispensable for the organogenesis of most lymphoid 
tissues, but is indispensable for optimal development of 
inflammatory lesions.19 This finding indicated that TNF-α 
activation by ectodomain shedding plays important roles 
in inflammatory diseases. Indeed, myeloid cell-specific 
ADAM17-deficient mice were protected from K/BxN 
STA.34 Moreover, the deletion of iRHOM2, a critical 
regulator of protein maturation and of the cell surface 
localisation of ADAM17, also protected against K/BxN 
STA,34 further indicating that ADAM17-mediated TNF-α 
shedding is involved in AAIA. Our previous studies have 
demonstrated that NRDC enhances ectodomain shed-
ding of TNF-α via activation of ADAM17.23 28 30 NRDC is 
one of the rare proteins that have been shown to bind 
directly to ADAM17 and enhance its enzymatic activity. 
Interestingly, the peptidase activity of NRDC is not 
required for the enhancement of ADAM17 activity.22–24 
These previous findings prompted us to examine the 
role of NRDC in autoimmune arthritis, and we found 
that inhibition of NRDC had a protective effect against 
the disease. We have demonstrated here that macro-
phage-specific deletion of NRDC closely recapitulated 
the resistant phenotype of whole-body knockout mice 
in AAIA models. Using BMDMs, PMs and THP-1 cells, 
we showed that NRDC regulates ectodomain shedding 
of TNF-α in macrophages and monocytic cells. A defi-
ciency of NRDC in all cell types resulted in a decrease 
in cleaved TNF-α, whereas TNF-α mRNA was not signifi-
cantly affected. These results strongly suggest that NRDC 
in macrophages is involved in the pathogenesis of AAIA 
via the regulation of TNF-α shedding.
It was previously reported that the level of TNF-α is 
increased in RA synovial fluid.37 We demonstrate here 
that the level of NRDC and TNF-α in synovial fluid is 
remarkably elevated in RA patients compared with that in 
OA patients. NRDC levels in RA synovial fluid correlated 
with synovial fluid TNF-α and serum CRP, suggesting that 
a local increase of NRDC in the RA joint may enhance 
TNF-α secretion, resulting in aggravation of joint 
inflammation. These results suggest that NRDC plays 
important roles not only in mouse experimental models 
of RA but also in RA patients, and therefore that gene-tar-
geted therapy with RNAi has potential in the treatment 
of RA.38 Intra-articular injection of anti-TNF-α siRNA was 
shown to inhibit collagen-induced arthritis in mice,39 and 
intravenous administration of double-stranded miR-451 
reduced arthritis in SKG mice via downregulation of 
neutrophil chemotaxis.40 We show here that intra-ar-
ticular injection of anti-Nrdc siRNA ameliorated CAIA. 
In this experiment, arthritis was induced more rapidly 
than without intra-articular injection, probably because 
of the inflammatory response against injected reagents 
or trauma associated with the injection. This significant 
attenuation of arthritis by anti-Nrdc siRNA provided an 
indication of a novel treatment for RA. Although biologic 
TNF-α blockers are widely used for the management of 
RA patients, complete inhibition of TNF-α might cause 
adverse effects, mainly infections, because a physiolog-
ical level of TNF-α secretion is necessary for the normal 
inflammatory response. As we show here, gene deletion 
or silencing of NRDC in macrophages and monocytic cells 
did not affect their baseline level of constitutive TNF-α 
production and secretion. Thus, anti-NRDC therapy 
could have the potential to reduce only excessive TNF-α 
secretion. In a similar sense, ADAM17 could be an alter-
native target for controlling TNF-α secretion. However, 
ADAM17 cleaves not only TNF-α but also a wide range of 
membrane proteins including EGF receptor ligands and 
Notch,41 which may cause side effects of ADAM17 inhib-
itor treatment in the skin, intestine and liver.34 42 In terms 
of substrates, NRDC also enhances ectodomain shed-
ding of various membrane proteins including HB-EGF, 
neuregulin1 and amyloid precursor protein.22 24 29 Other 
than TNF-α, several membrane proteins considered to 
be important for RA pathogenesis, such as TNF recep-
tors and IL-6 receptors, are also functionally regulated 
by ectodomain shedding. NRDC-mediated regulation of 
the shedding of these molecules might contribute to the 
attenuation of arthritis by the deletion of NRDC.
Apart from its extracellular function as an enhancer 
of ectodomain shedding, a nuclear function of NRDC 
as a transcriptional coregulator has been recently clari-
fied. The roles of NRDC in transcriptional regulation 
were illustrated by the interaction of NRDC with various 
nuclear proteins such as histone deacetylase 3, peroxi-
some proliferator-activated receptor gamma coactivator 
1-α and islet1.43–45 Intriguingly, the nuclear function of 
NRDC is crucially involved in adaptive thermogenesis44 
and insulin secretion in vivo.43 Although we cannot 
exclude a possible involvement of nuclear NRDC in 
AAIA, we demonstrate here that mRNA levels of TNF-α 
and ADAM17 in macrophages are not affected by the 
inhibition of NRDC, suggesting that it is extracellular 
NRDC that mainly regulates AAIA.
Another limitation of this study is that we have not 
clarified NRDC function in neutrophils, which have 
a role in the pathogenesis of AAIA.33 Because the Lyz2 
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gene is expressed not only in macrophages but also in 
neutrophils,46 NRDC in neutrophils should be deleted in 
NrdcdelM mice.
In summary, our results demonstrated for the first 
time that NRDC is involved in AAIA at least partially 
via enhancement of TNF-α shedding in macrophages. 
NRDC levels in synovial fluid are increased in RA patients 
and correlate with systemic inflammation, providing a 
new insight into the pathogenesis of RA. In addition, 
we showed that Nrdc gene silencing ameliorates arthritis 
in mouse experimental models of RA, suggesting that 
NRDC could be a new therapeutic target for RA.
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